V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005195 | 330002490 | 1.72 | 75.9 | Curative (C) | 2017-03-17 | 2017-11-25 | IVADo | N | N | 330022016 | ADE |
| 330005196 | 330002490 | 1.6 | 54.3 | Palliative (P) | 2015-01-19 | 2015-02-01 | Doxorubicin + Olaratumab | N | N | 330022016 | PEMBROLIZUMAB |
| 330005197 | 330002490 | null | 70 | Adjuvant (A) | null | 2013-11-09 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | null | null | 330022016 | CISPLATIN + DOCETAXEL |
| 330005198 | 330002490 | 1.6 | 91.8 | Not known (9) | 2016-05-23 | 2016-05-24 | MITOTANE | N | N | 330022016 | CARBOPLATIN + RT |
| 330005199 | 330002490 | 1.71 | 55.1 | Palliative (P) | 2018-06-24 | 2018-06-24 | OST Euramos 1 Closed Trial - M | N | N | 330022016 | PEMBROLIZUMAB |
| 330005200 | 330002490 | 1.7 | 108.9 | Disease modification (D) | null | 2018-06-26 | FLUOROURACIL + MITOMYCIN + RT | N | N | 330022016 | IVA |
| 330005201 | 330002491 | 1.31 | null | Not known (9) | 2016-11-19 | 2016-11-25 | FLUDARABINE | 02 | N | 330022092 | DOCETAXEL |
| 330005202 | 330002492 | 1.74 | 0 | Curative (C) | null | 2014-07-12 | Hydroxycarbamide | N | N | 330022097 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330005203 | 330002492 | 1.68 | 67.8 | Curative (C) | 2013-05-11 | 2013-05-11 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 330022097 | PACLITAXEL |
| 330005204 | 330002492 | 1.6 | 54.5 | Palliative (P) | 2016-01-21 | 2016-01-21 | GC Int Guide Excranial GermCell JEB | N | N | 330022097 | CARBOPLATIN + VINCRISTINE |
| 330005205 | 330002493 | 0.86 | null | Curative (C) | 2013-07-13 | 2013-07-19 | ALL UKALL2011 Ind B Sht Dex (PAsp) | N | N | 330022131 | EVEROLIMUS |
| 330005206 | 330002493 | null | 76.7 | Curative (C) | 2013-09-17 | 2013-09-21 | Chlorambucil | N | N | 330022131 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330005207 | 330002493 | 1.58 | 72.1 | Palliative (P) | 2018-07-06 | 2018-07-10 | Mitotane 3 - 3.5g | 02 | N | 330022131 | SUNITINIB |
| 330005208 | 330002494 | 1.74 | 59.5 | Curative (C) | 2015-03-21 | 2015-03-28 | Docetaxel | N | N | 330022148 | VIDE |
| 330005209 | 330002494 | 1.71 | 82.2 | Curative (C) | 2017-12-06 | 2017-12-17 | VEPEMB | 02 | N | 330022148 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330005210 | 330002495 | null | null | null | 2014-11-03 | 2014-11-04 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 2 | N | 330022157 | IVA |
| 330005211 | 330007372 | 1.65 | 12.5 | Not known (9) | 2017-10-04 | 2017-09-28 | EMA/CO | 02 | null | 330022158 | CAPECITABINE + OXALIPLATIN |
| 330005212 | 330002496 | null | 64.8 | Palliative (P) | null | 2015-03-12 | ICE-R (Cycle 2 onwards) | Y | N | 330022163 | DOXORUBICIN + OLARATUMAB |
| 330005213 | 330002496 | 1.67 | 24.4 | Palliative (P) | 2013-06-13 | 2013-06-14 | Azacitidine | 02 | N | 330022163 | IMATINIB |
| 330005215 | 330007374 | 0 | null | null | 2015-05-05 | 2015-05-08 | Doxorubicin + Ifosfamide | Y | N | 330022185 | CVD (NEUROENDOCRINE) |
| 330005216 | 330007374 | 1.82 | 76 | Curative (C) | 2017-11-16 | 2017-11-16 | ADE 10+3+5 | 02 | N | 330022185 | DOXORUBICIN + IFOSFAMIDE |
| 330005217 | 330002498 | 1.67 | 75.4 | Palliative (P) | 2018-09-15 | 2018-09-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | null | 330022207 | CHLORAMBUCIL |
| 330005218 | 330002498 | 1.62 | 11.8 | Curative (C) | 2014-09-09 | 2014-09-09 | Methotrexate + Folinic acid | 02 | N | 330022207 | AML19 TRIAL |
| 330005219 | 330002498 | 1.76 | 70 | Palliative (P) | 2013-12-20 | 2013-12-20 | TCF | 02 | Y | 330022207 | TVD |
| 330005220 | 330002498 | 1.49 | 72.35 | Curative (C) | 2014-09-20 | 2014-09-21 | PACLITAXEL | 2 | N | 330022207 | CAV |
| 330005221 | 330002498 | 1.68 | 67.25 | Palliative (P) | 2014-10-04 | 2014-10-05 | CARBOPLATIN + RT | 02 | N | 330022207 | CISPLATIN + FLUOROURACIL + RT |
| 330005222 | 330012705 | 1.53 | 0 | Disease modification (D) | 2017-02-15 | 2017-02-16 | Mitotane 2g | N | N | 330022240 | OXALIPLATIN + MDG |
| 330005223 | 330012705 | 1.63 | 96.45 | Palliative (P) | 2017-06-29 | 2017-06-29 | EVEROLIMUS | N | N | 330022240 | IFOSFAMIDE |
| 330005224 | 330012705 | 0 | 58 | Palliative (P) | 2016-06-30 | 2016-08-05 | Azacitidine | N | N | 330022240 | CAPECITABINE + OXALIPLATIN |
| 330005225 | 330012705 | 1.67 | 67 | Adjuvant (A) | 2017-11-29 | 2017-11-30 | CARBOPLATIN + RT | 02 | N | 330022240 | UKALL2011 |
| 330005226 | 330012705 | 1.77 | null | null | null | 2017-08-27 | Cetuximab +Cisplatin + FU (Cycle 1) | null | null | 330022240 | CISPLATIN + VINORELBINE |
| 330005227 | 330002499 | 1.61 | 43.4 | null | 2018-08-17 | 2018-08-17 | Trastuzumab Subcutaneous | N | N | 330022274 | CLADRIBINE |
| 330005228 | 330007376 | 1.8 | 80 | Neo-adjuvant (N) | 2014-06-06 | 2014-06-13 | Chlorambucil | 02 | N | 330022292 | CARBOPLATIN + RT |
| 330005229 | 330002500 | 1.67 | 7.7 | Not known (9) | 2013-05-16 | 2013-06-06 | CAPECITABINE + MITOMYCIN + RT | N | N | 330022302 | FLUOROURACIL + MITOMYCIN + RT |
| 330005230 | 330002500 | 1.54 | 63 | Curative (C) | 2014-04-03 | 2014-04-03 | FLUOROURACIL + MITOMYCIN | 2 | N | 330022302 | DOXORUBICIN + OLARATUMAB |
| 330005231 | 330002500 | null | 13.2 | Disease modification (D) | 2017-07-07 | 2017-07-23 | ALL UKALL 2011 HD MtxA (Protocol M) | N | null | 330022302 | CAPECITABINE + CARBOPLATIN |
| 330005232 | 330002501 | null | 39 | Palliative (P) | 2015-04-19 | 2015-04-19 | AML16 DA 3+10 | N | N | 330022329 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330005233 | 330007378 | 1.79 | 99 | Disease modification (D) | null | 2016-05-10 | Sunitinib | 2 | N | 330022340 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330005234 | 330007378 | 1.66 | 89.15 | Disease modification (D) | 2014-12-10 | 2014-12-13 | Cisplatin + Vinorelbine (PO) | 02 | null | 330022340 | VINBLASTINE |
| 330005235 | 330007378 | 1.7 | 89.3 | Palliative (P) | 2017-07-18 | 2017-07-19 | IMATINIB | 02 | Y | 330022340 | DOCETAXEL |
| 330005236 | 330007378 | null | null | Neo-adjuvant (N) | 2014-01-06 | 2014-01-31 | Pazopanib | 99 | N | 330022340 | PCV |
| 330005237 | 330007378 | 1.59 | 0 | Palliative (P) | 2015-12-15 | 2015-12-15 | CAPECITABINE + CISPLATIN + EPIRUBICIN | 02 | N | 330022340 | AZACITIDINE |
| 330005238 | 330007378 | 1.63 | 67.5 | null | 2013-11-04 | 2013-11-15 | Paclitaxel 7 day | N | N | 330022340 | DOXORUBICIN + IFOSFAMIDE |
| 330005239 | 330002502 | 1.6 | 51.1 | Curative (C) | 2017-06-22 | 2017-07-13 | CYCLO + RITUXIMAB + VINCRISTINE | null | null | 330022373 | FLUOROURACIL + MITOMYCIN |
| 330005240 | 330002503 | 1.7 | null | null | 2014-04-01 | 2014-04-07 | CNS HGG Temozolomide maintenance | N | null | 330022381 | VEMURAFENIB |
| 330005241 | 330002504 | 1.7 | null | Disease modification (D) | 2013-03-26 | 2013-03-31 | VAI (Ifos 3g/m2) | N | N | 330022396 | PEMBROLIZUMAB |
| 330005242 | 330002504 | 1.6 | 112.3 | Palliative (P) | 2016-01-26 | 2016-02-10 | CHOP - 21 days | null | null | 330022396 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330005243 | 330002504 | 1.5 | 39 | Disease modification (D) | 2013-12-19 | 2013-12-19 | TEMOZOLOMIDE | 02 | N | 330022396 | DOXORUBICIN + IFOSFAMIDE |
| 330005244 | 330002505 | 1.64 | null | Palliative (P) | 2016-02-26 | 2016-03-04 | OST Euramos 1 Closed Trial - M | N | N | 330022399 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330005245 | 330002505 | 1.58 | 11.3 | Palliative (P) | 2017-01-07 | 2017-01-09 | Cisplatin+Doxorubicin+Etoposide 28d | N | N | 330022399 | FLAG + IDARUBICIN |